Serum Alanine Aminotransferase Level as a Risk Factor for Coronary Heart Disease Prediction in Koreans: Analysis of the Korea National Health and Nutrition Examination Survey (V-1, 2010 and V-2, 2011)
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The blood level of alanine aminotransferase (ALT) is associated with increased coronary heart dis-ease (CHD) risk. However, its use as an independent factor for CHD risk prediction remains unclear in Asian popu-lations. The purpose of this study was to examine the association between serum ALT levels and CHD risk in Kore-ans.Methods: This was a cross-sectional study using data from the Korea National Health and Nutrition Examination Survey (V-1, 2010 and V-2, 2011). The ALT levels of 3,215 individuals were analyzed. The Framingham Risk Score (FRS) modified by the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) was used to compute the 10-year CHD risk prediction.Results: Positive correlations were established between log-transformed ALT concentration and FRS (r=0.433, P<0.001). After adjusting for body mass index, low-density lipoprotein cholesterol, the amount of alcohol intake, and gamma-glutamyl transferase, the odds ratio (95% confidence interval) for intermediate or greater risk of 10-year CHD prediction (10-year risk ≥10%) for the lowest quartile of participants was 2.242 (1.405–3.577) for the sec-ond quartile, 2.879 (1.772–4.679) for the third quartile, and 3.041 (1.789–5.170) for the highest quartile.Conclusion: In Koreans, a higher serum ALT concentration was significantly correlated with 10-year CHD risk pre-diction according to NCEP ATP III guidelines.
Abstract
Background: The blood level of alanine aminotransferase (ALT) is associated with increased coronary heart dis-ease (CHD) risk. However, its use as an independent factor for CHD risk prediction remains unclear in Asian popu-lations. The purpose of this study was to examine the association between serum ALT levels and CHD risk in Kore-ans.Methods: This was a cross-sectional study using data from the Korea National Health and Nutrition Examination Survey (V-1, 2010 and V-2, 2011). The ALT levels of 3,215 individuals were analyzed. The Framingham Risk Score (FRS) modified by the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) was used to compute the 10-year CHD risk prediction.Results: Positive correlations were established between log-transformed ALT concentration and FRS (r=0.433, P<0.001). After adjusting for body mass index, low-density lipoprotein cholesterol, the amount of alcohol intake, and gamma-glutamyl transferase, the odds ratio (95% confidence interval) for intermediate or greater risk of 10-year CHD prediction (10-year risk ≥10%) for the lowest quartile of participants was 2.242 (1.405–3.577) for the sec-ond quartile, 2.879 (1.772–4.679) for the third quartile, and 3.041 (1.789–5.170) for the highest quartile.Conclusion: In Koreans, a higher serum ALT concentration was significantly correlated with 10-year CHD risk pre-diction according to NCEP ATP III guidelines.
참고문헌 (29)
- Price C, "Liver and biliary diseases: pathophysiology, diagnosis, management", pp.381~416 (1979), W.B. Saunders
- Torres DM, "NAFLD : predictive value of ALT levels for NASH and advanced fibrosis", Nat Rev Gastroenterol Hepatol, 10, pp.510~511 (2013)
- Cao W, "Cytokeratin 18, alanine aminotransferase, platelets and triglycerides predict the presence of nonalcoholic steatohepatitis", PLoS One, 8, pp.e82092~ (2013)
- Carobene A, "A systematic review of data on biological variation for alanine aminotransferase, aspartate aminotransferase and g-glutamyl transferase", Clin Chem Lab Med, 51, pp.1997~2007 (2013)
- Gurung RB, "The ratio of aspartate aminotransferase to alanine aminotransferase (AST", ALT): the correlation of value with underlying severity of alcoholic liver disease, 2013, pp.11, 233~236
- Marchesini G, "Nonalcoholic fatty liver disease : a feature of the metabolic syndrome", Diabetes, 50, pp.1844~1850 (2001)
- Westerbacka J, "Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women : implications for sex differences in markers of cardiovascular risk", Diabetologia, 47, pp.1360~1369 (2004)
- Cortez-Pinto H, "Non-alcoholic fatty liver : another feature of the metabolic syndrome", Clin Nutr, 18, pp.353~358 (1999)
- Knobler H, "Fatty liver : an additional and treatable feature of the insulin resistance syndrome", QJM, 92, pp.73~79 (1999)
- Gupte P, "Non-alcoholic steatohepatitis in type 2 diabetes mellitus", J Gastroenterol Hepatol, 19, pp.854~858 (2004)
- Hanley AJ, "Liver markers and development of the metabolic syndrome : the insulin resistance atherosclerosis study", Diabetes, 54, pp.3140~3147 (2005)
- Dekker JM, "Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study", Circulation, 112, pp.666~673 (2005)
- Schindhelm RK, "Alanine aminotransferase predicts coronary heart disease events : a 10-year follow-up of the Hoorn Study", Atherosclerosis, 191, pp.391~396 (2007)
- Greenfield TK, "Ways of measuring drinking patterns and the difference they make : experience with graduated frequencies", J Subst Abuse, 12, pp.33~49 (2000)
- Anthony D, "Cardiac risk factors : biomarkers and genetic tests to determine cardiovascular risk", FP Essent, 421, pp.11~15 (2014)
- Dalen JE, "The epidemic of the 20(th)century : coronary heart disease", Am J Med, 127, pp.807~812 (2014)
- Verma S, "Predictive value of ALT levels for non-alcoholic steatohepatitis(NASH)and advanced fibrosis in non-alcoholic fatty liver disease(NAFLD)", Liver Int, 33, pp.1398~1405 (2013)
- Lu H, "High prevalence of coronary heart disease in type 2 diabetic patients with non-alcoholic fatty liver disease", Arch Med Res, 40, pp.571~575 (2009)
- Gaggini M, "Non-alcoholic fatty liver disease(NAFLD)and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease", Nutrients, 5, pp.1544~1560 (2013)
- Targher G, "Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease", Hepatology, 53, pp.375~ (2011)
- Lonardo A, "Cardiovascular and systemic risk in nonalcoholic fatty liver disease : atherosclerosis as a major player in the natural course of NAFLD", Curr Pharm Des, 19, pp.5177~5192 (2013)
- Charlton M, "Apolipoprotein synthesis in nonalcoholic steatohepatitis", Hepatology, 35, pp.898~904 (2002)
- Gianturco SH, "Lipoprotein-mediated cellular mechanisms for atherogenesis in hypertriglyceridemia", Semin Thromb Hemost, 14, pp.165~169 (1988)
- Shen J, "Correlation of serum alanine aminotransferase and aspartate aminotransferase with coronary heart disease", Int J Clin Exp Med, 8, pp.4399~4404 (2015)
- Kerner A, "Association between elevated liver enzymes and C-reactive protein : possible hepatic contribution to systemic inflammation in the metabolic syndrome", Arterioscler Thromb Vasc Biol, 25, pp.193~197 (2005)
- Cinkajzlova A, "Lymphocytes and macrophages in adipose tissue in obesity : markers or makers of subclinical inflammation", Protoplasma, 254, pp.1219~1232 (2017)[DOI]
- Ioannou GN, "Implications of elevated serum alanine aminotransferase levels : think outside the liver", Gastroenterology, 135, pp.1851~1854 (2008)
- Yamada J, "Elevated serum levels of alanine aminotransferase and gamma glutamyltransferase are markers of inflammation and oxidative stress independent of the metabolic syndrome", Atherosclerosis, 189, pp.198~205 (2006)
- Bruckert E, "A constellation of cardiovascular risk factors is associated with hepatic enzyme elevation in hyperlipidemic patients", Metabolism, 51, pp.1071~1076 (2002)